Navigation Links
Tarsa Therapeutics Signs Commercial Supply Agreement for its Ostora™ Oral Calcitonin Product With QS Pharma
Date:3/21/2012

Pharma commented, "This new commercial supply agreement with Tarsa Therapeutics is especially gratifying because it reflects the excellence of the work we have conducted for the company during the clinical development of OSTORA.  We appreciate their continuing confidence and look forward to the opportunity to support the successful commercialization of the first-ever oral calcitonin product expected to reach the market."

Tarsa's oral calcitonin is also being assessed in a one-year double-blind Phase II study comparing the OSTORA tablet to placebo in postmenopausal women who have low bone mass (osteopenia) and are at increased risk of fracture.  The study is evaluating the ability of oral calcitonin to prevent osteoporosis and maintain bone mass in this population. 

Tarsa is developing its OSTORA oral calcitonin under a licensing agreement with Unigene Laboratories that provides Tarsa with exclusive development and worldwide commercialization rights to Unigene's oral calcitonin product, with the exception of China.

About QS Pharma
QS Pharma, located near Philadelphia in Boothwyn, PA, provides a broad range of contract development/research and clinical/commercial manufacturing services for pharmaceutical and biopharmaceutical companies worldwide.  Founded on the tenet of Quality with Speed™, QS Pharma has extensive pharmaceutical product development expertise and knowledge.  Its facility consists of over 43,000 sq ft of analytical laboratories and drug product manufacturing space with state-of-the-art cGMP manufacturing suites that can accommodate batch sizes ranging from <1kg to over 300kg.  For more information, see www.qspharma.com.

About Tarsa Therapeutics
Tarsa Therapeutics is developing OSTORA™, a novel oral formulation of calcitonin for the treatment and prevention of postmenopausal osteoporosis.  OSTORA is expected
'/>"/>

SOURCE Tarsa Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Tarsa Therapeutics Presents Positive Efficacy and Safety Data Comparing Its Oral Calcitonin to Nasal Calcitonin and Placebo in Phase III Osteoporosis Treatment Trial
2. Tarsa Therapeutics Reports Positive Top-Line Results From Pivotal Phase III ORACAL Trial of its Oral Calcitonin in Treatment of Postmenopausal Osteoporosis
3. Tarsa Therapeutics Completes Phase III Trial of its Oral Calcitonin for Treatment of Postmenopausal Osteoporosis and Initiates Phase II Trial in Osteoporosis Prevention
4. Novation Releases Its Latest Transcatheter Cardiovascular Therapeutics Report to Help Members Understand and Prepare for New Technologies
5. Halo Therapeutics Reports Favorable Independent Review of Lead Drug Candidate HT-100
6. Echo Therapeutics, Inc. Announces 2011 Financial Results
7. Stemline Therapeutics Appoints Kevin Buchi, Former CEO of Cephalon, to Its Board of Directors
8. Nile Therapeutics Announces Upcoming Data Presentation at the American College of Cardiology Annual Scientific Meeting
9. Prime Therapeutics Announces CareCentered Contract™ with EMD Serono, Inc. for MS Drug Rebif®
10. ADHD Therapeutics Reviewed by NeuroPerspective
11. Cell Therapeutics, Inc. (CTI) Reports Fourth Quarter and Year-End Financial Results and Milestones
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)...  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO )("NW Bio"), a ... and inoperable solid tumor cancers, announced today that CEO ... Annual Phacilitate Immunotherapy Forum in Washington D.C. ... place on January 26 at 10:30 a.m. EST at the ...
(Date:1/23/2015)... all-time hits leader, is the new spokesperson for the topical ... announced. "Pete,s a Hall of Famer in our ... with Myoflex," said Ducere Pharma Chief Executive Officer Chris ... across all generations. The passion and intensity that Pete brought ...
(Date:1/23/2015)... Cord Blood America, Inc. ( www.cordblood-america.com ) (OTC Bulletin Board: ... Preliminary Proxy Statement, Schedule 14A, with the U.S. Securities & ... for shareholders detailing why a "YES" vote to increase the ... As we reflect upon the 2014 fiscal year ...
Breaking Medicine Technology:NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Pete Rose bets on Myoflex to relieve aches and pains 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4
... Cetero Research , the leading early-stage contract ... "Jay" Dixon to Senior Vice President, Quality and Compliance. ... pharmaceutical, biotechnology and CRO industries, and will bring his ... market leadership position. (Photo:   http://photos.prnewswire.com/prnh/20110426/PH89541 ...
... Protect Pharmaceutical Corporation (OTCBB: PRTT) today announced its Board ... Sesha as its Chief Executive Officer and Chairman of ... the Chief Operating Officer and Board Member in March ... where he was the Founder and CEO. ...
Cached Medicine Technology:Cetero Research Names 25-Year Industry Veteran James Dixon to Head Quality and Compliance 2Protect Pharmaceutical Corporation Appoints Chief Executive Officer and Chief Financial Officer 2
(Date:1/22/2015)... with its top dressmaking technologies, has been a leading dress ... its latest designs of wedding dresses and launching a site-wide ... all the fresh new products are designed for 2015, and ... off. All the clothes from LunaDress follow up with the ...
(Date:1/22/2015)... 22, 2015 Padre Murphy's and Owner Tom ... Pro Player Health Alliance (PPHA). The PPHA's passion ... getting everyone, including NFL greats, treated for obstructive sleep apnea ... groups supporting the cause in the valley. The most recent ...
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota (Blue Cross) wants ... “Live Fearless.” , The “Faces of Fearless” campaign ... how they or someone they know has faced a challenge, ... moment. By telling these types of stories through livefearlessmn.com, participants ...
(Date:1/22/2015)... A new white paper by The Beryl Institute ... long-term care environment as well as provides recommendations for ... “The Power of Person-Centeredness in Long-Term Care: A View ... patient, resident and family experience in long-term care and ...
(Date:1/22/2015)... released a new blog post presenting the basic features of ... an accidental death and dismemberment rider for a car insurance ... benefits if the insured dies in an accident. Accidental death ... insurance. , AD&D is not expensive and can be ...
Breaking Medicine News(10 mins):Health News:LunaDress Shows The Latest Styles Of Wedding Dresses In 2015 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2
... to revolutionize senior home care industry!PALO ALTO, Calif., ... Alto, California released its new caregiver training program ... exclusive to Home Care Assistance 1-866-4-LiveIn(TM), promotes longevity ... an emphasis on lifestyle, healthy diet, physical activity, ...
... Kidz-Med ThermofocusWESTON, Fla., May 22 Kidz-Med, Inc., a ... is excited to see that awareness for a new ... taking a child,s temperature with the Kidz-Med Thermofocus 5-in-1 ... The Doctors , renowned pediatrician Dr. Jim Sears, ...
... 22 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. ("Bioniche"; ... today provided an update on its Phase III ... bladder cancer. On March 31st, the Company announced ... Phase III registration trial evaluating Urocidin in the ...
... protein linked to tumor growth for clues to better treatments ... have found that levels of the protein caveolin-1 found in ... predict a patient,s prognosis and may provide a pathway to ... a role in how cells absorb things, in the stromal ...
... is what leads to well-being , , FRIDAY, May 22 (HealthDay ... may sound like a sure ticket to happiness, but a ... Rochester in New York tracked 147 college graduates, evaluating their ... one year after graduation, and then 12 months later. , ...
... to manufacturers by month,s end , , FRIDAY, May 22 (HealthDay ... a bit nearer Friday, with government health officials saying they ... shot. , "Today CDC received, from one institution, a candidate ... Science and Public Health Program said during a Friday news ...
Cached Medicine News:Health News:Home Care Assistance's Exclusive Balanced Care Method(TM) Designed to Promote Longer, Healthier Lives 2Health News:Home Care Assistance's Exclusive Balanced Care Method(TM) Designed to Promote Longer, Healthier Lives 3Health News:Awareness Increases on New Health and Safety Technology for Kids 2Health News:Awareness Increases on New Health and Safety Technology for Kids 3Health News:Bioniche Phase III Clinical Trial with Urocidin(TM) Progressing Well 2Health News:Bioniche Phase III Clinical Trial with Urocidin(TM) Progressing Well 3Health News:Looks, Money, Fame Don't Bring Happiness 2Health News:CDC Has Candidate Viruses for Swine Flu Vaccine 2Health News:CDC Has Candidate Viruses for Swine Flu Vaccine 3Health News:CDC Has Candidate Viruses for Swine Flu Vaccine 4Health News:CDC Has Candidate Viruses for Swine Flu Vaccine 5Health News:CDC Has Candidate Viruses for Swine Flu Vaccine 6Health News:CDC Has Candidate Viruses for Swine Flu Vaccine 7Health News:CDC Has Candidate Viruses for Swine Flu Vaccine 8Health News:CDC Has Candidate Viruses for Swine Flu Vaccine 9Health News:CDC Has Candidate Viruses for Swine Flu Vaccine 10Health News:CDC Has Candidate Viruses for Swine Flu Vaccine 11Health News:CDC Has Candidate Viruses for Swine Flu Vaccine 12Health News:CDC Has Candidate Viruses for Swine Flu Vaccine 13
Nucleus divider with 1.25 mm tip and blade offset at a 60 degree angle is ideal for performing the "Phaco Chop" technique. Round knurled handle. Manufactured in titanium....
#2 10 mm hook. Flat serrated handle with polished finish. Overall length: 5.5 inches....
7 mm flattened hook. Flat serrated handle with polished finish. Overall length: 4.9 inches....
Left angled 5 mm blunt hook. Overall length: 9.9 inches....
Medicine Products: